Vaccination strategies for neuro-oncology.

Published

Journal Article (Review)

Vaccination against cancer-associated antigens has long held the promise of inducting potent antitumor immunity, targeted cytotoxicity while sparing normal tissues, and long-lasting immunologic memory that can provide surveillance against tumor recurrence. Evaluation of vaccination strategies in preclinical brain tumor models has borne out the capacity for the immune system to effectively and safely eradicate established tumors within the central nervous system. Early phase clinical trials have established the feasibility, safety, and immunogenicity of several vaccine platforms, predominantly in patients with glioblastoma. Definitive demonstration of clinical benefit awaits further study, but initial results have been encouraging. With increased understanding of the stimulatory and regulatory pathways that govern immunologic responses and the enhanced capacity to identify novel antigenic targets using genomic interrogation of tumor cells, vaccination platforms for patients with malignant brain tumors are advancing with increasing personalized complexity and integration into combinatorial treatment paradigms.

Full Text

Duke Authors

Cited Authors

  • Sampson, JH; Mitchell, DA

Published Date

  • November 2015

Published In

Volume / Issue

  • 17 Suppl 7 /

Start / End Page

  • vii15 - vii25

PubMed ID

  • 26516221

Pubmed Central ID

  • 26516221

Electronic International Standard Serial Number (EISSN)

  • 1523-5866

Digital Object Identifier (DOI)

  • 10.1093/neuonc/nov159

Language

  • eng

Conference Location

  • England